Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PD-L1+ CTCs Are Associated with Adverse Pathological Features and Unfavorable Prognosis in Bladder Cancer.

Diagnostics (Basel, Switzerland)·2026
Same author

A nomogram including body composition parameters for predicting recurrence of pT1 clear cell renal cell carcinoma: a multicenter retrospective study.

Insights into imaging·2026
Same author

Safety and feasibility of prone retroperitoneal robotic-assisted partial nephrectomy (prRAPN): a novel posterior approach and perioperative results - a prospective study.

World journal of urology·2025
Same author

SRSF1-mediated alternative splicing regulates bladder cancer progression and cisplatin sensitivity through HIF1A/BNIP3/mitophagy axis.

Journal of translational medicine·2025
Same author

Deep learning on T2WI to predict the muscle-invasive bladder cancer: a multi-center clinical study.

Scientific reports·2025
Same author

Letter to the editor: Multiparametric MRI-based VI-RADS: Can it predict 1- to 5-year recurrence of bladder cancer?

European radiology·2024

Related Experiment Video

Updated: Jul 16, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

An Immunohistochemistry-Based Molecular Subtyping Approach for Capturing Clinical Outcome Heterogeneity in Bladder

Yuhan Chen1, Lingkai Cai1, Xiao Yang1

  • 1Department of Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210000, China.

Diagnostics (Basel, Switzerland)
|July 15, 2026
PubMed
Summary

Bladder cancer molecular subtypes, luminal and non-luminal, show distinct responses to neoadjuvant chemotherapy (NAC) and survival outcomes. Luminal tumors have poorer pathological response but better overall survival, highlighting subtype-specific treatment strategies.

Keywords:
bladder cancerimmunohistochemistrymolecular subtyping

More Related Videos

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

Related Experiment Videos

Last Updated: Jul 16, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

Area of Science:

  • Oncology
  • Pathology
  • Molecular Biology

Background:

  • Bladder cancer exhibits significant biological heterogeneity, impacting clinical course and prognosis.
  • Immunohistochemistry-based molecular subtyping can delineate clinically relevant differences in bladder cancer.

Purpose of the Study:

  • To use immunohistochemistry to classify bladder tumors into luminal and non-luminal subtypes.
  • To analyze associations between molecular subtypes, histopathological features, chemotherapy response, and survival outcomes.

Main Methods:

  • Retrospective analysis of 590 bladder cancer patients.
  • Tumor stratification into luminal/non-luminal based on CK20, GATA3, CK5/6, and CK14 expression.
  • Evaluation of survival endpoints (OS, RFS, PFS) using Kaplan-Meier and Cox regression analyses.

Main Results:

  • Non-luminal tumors showed more aggressive pathological patterns (e.g., tumor budding, spindle cell architecture).
  • Non-luminal tumors had a higher pathological complete response (pCR) rate after neoadjuvant chemotherapy (NAC).
  • Luminal tumors demonstrated significantly better overall survival (OS), recurrence-free survival (RFS), and progression-free survival (PFS) despite lower pCR rates.

Conclusions:

  • Bladder cancer molecular subtypes exhibit distinct trajectories for pathological response and long-term survival.
  • Favorable pathological response does not always correlate with improved long-term survival across molecular subtypes.
  • Molecular subtype is an independent predictor of OS, with luminal tumors having a lower mortality risk.